Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) reported Q3 EPS of $0.15, $0.19 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $1.18 million.

For earnings history and earnings-related data on Oramed Pharmaceuticals Inc. (ORMP) click here.